ARTEMIS and Taconic Acquire Chemical Genetics Technology From CGI Pharmaceuticals, Inc.

04-May-2007

Taconic Farms, Inc. and Artemis Pharmaceuticals GmbH announced that they have jointly acquired the worldwide rights to the ASKA technology from CGI Pharmaceuticals Inc. ASKA technology is based on the Replacement of a normal kinase with a selectively modified kinase or "ASKA" (Analogue Sensitive Kinase Allele) in genetically modified mice.

Under the terms of the transaction, ARTEMIS and Taconic are assigned the entire portfolio of ASKA intellectual property rights (including all ASKA IP that CGI had previously licensed exclusively from Princeton University) as well as know-how, trade secrets and materials developed by CGI. Included are the rights to patents based on the chemistry and molecular biology work of Dr. Kevan Shokat, inventor of the ASKA technology. Financial details of the transaction were not disclosed.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances